Home > Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma
Haematological Malignancies, Lymphoma

Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma

Published Online: June 27th 2019

At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma.

Questions

1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05)
2. What is the role of brentuximab vedotin in the current treatment paradigm for HL? (2:10)
3. How is the role of brentuximab vedotin likely to further evolve in the treatment of HL? (3:33)
4. How can immune checkpoint inhibitors best fit into the treatment paradigm for HL? (4:45)
5. What emerging therapeutic options seem most promising in the future treatment of HL? (5.30)

Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.

Share this Video
Related Videos In Lymphoma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar